Protego to Highlight PROT-001's Potential to Target Light Chain Toxicity in AL Amyloidosis at ISA 2026
Image File
Original HTML

- Phase 1 results in healthy volunteers characterize the clinical profile of PROT-001, an investigational first-in-class lambda light chain kinetic stabilizer

- Preclinical presentations to evaluate PROT-001's potential to reduce light chain-induced cardiac toxicity in AL amyloidosis and its compatibility with bortezomib-based treatment

- AmyLiteDx⢠Assay and presentations that highlight advances in pharmacodynamic and clinical activity measures for PROT-001 development

SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small-molecule therapies for protein misfolding diseases, today announced five presentations at the XX International Symposium on Amyloidosis (ISA 2026), taking place November 15â18, 2026.

The presentations follow the company's recently announced FDA clearance to proceed with its Phase 2/3 SHIELD-AL study, which will evaluate PROT-001 added to standard of care in patients with AL amyloidosis.

"PROT-001 was designed to stabilize amyloidogenic light chains and neutralize their toxicity, providing a distinct approach that could complement therapies directed at the plasma cells that produce them," said Brent J. Warner, MBA, Chief Executive Officer of Protego. "As we initiate SHIELD-AL, we believe our approach could help patients achieve faster and deeper organ responses beyond standard of care alone. Deeper cardiac responses are associated with improved survival, underscoring the potential of PROT-001 to make a meaningful difference for patients."

Protego's presentations at ISA 2026 will include four Discussed E-poster presentations and one traditional poster presentation:

Title: PROT-001, a first in class lambda light chain kinetic stabilizer for AL amyloidosis: Results from the Phase I PRO-1A-101 Study

- Abstract Number: 32458

- Session: E-poster Session 1 - Treatments of AL

- Presentation Date and Time: Monday, November 16, 2026; 10:35 AM - 11:00 AM

Title: PROT-001 Demonstrates Compatibility with Bortezomib-Based Regimens While Preserving Plasma Cell Cytotoxicity

- Abstract Number: 32147

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: PROT-001 Suppresses Amyloidogenic Light Chain Induced BNP Signaling and Cardiotoxicity in Human Cardiomyocytes

- Abstract Number: 32266

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: AmyLiteDx: A Mass Spectrometry-Based Platform for Sensitive and In-Depth Analysis of Amyloidogenic Immunoglobulin Light Chains in AL Amyloidosis

- Abstract Number: 32645

- Session: E-poster Session 10 - Basic Science AL + Other More Rare Amyloidoses

- Presentation Date and Time: Tuesday, November 17, 2026; 11:00 AM - 12:00 PM

Title: Retrospective Study Evaluating Cardiac Biomarkers in Patients with AL Cardiac Amyloidosis

- Abstract Number: 32646

- Session: General Poster Session

- Presentation Date and Time: Tuesday, November 17, 2026

About Protego Biopharma

Protego Biopharma is a clinical-stage biotechnology company developing first-in-class small molecule therapies for AL amyloidosis and other protein misfolding diseases. Protego aims to translate advances in protein stabilization into medicines that address the misfolding and toxicity responsible for progressive organ damage. Its therapies are designed to intervene in this disease process, with the goal of preserving organ function and improving patients' lives. For more information, visit www.protegobio.com.

About PROT-001

PROT-001 is Protego Biopharma's lead investigational small molecule pharmacological chaperone, being developed for the treatment of immunoglobulin light chain (AL) amyloidosis. PROT-001 is designed to stabilize amyloidogenic lambda light chain proteins and prevent their misfolding and the formation of proteotoxic species. The goal of this therapy is limiting the toxic effects that contribute to organ injury, including direct damage to cardiomyocytes in AL patients. PROT-001 represents a complementary approach to plasma cell-directed therapies, which reduce light chain production. By targeting the amyloidogenic light chain protein itself before it can adopt a pathogenic conformation, PROT-001 has the potential to complement existing treatments and address an additional mechanism of disease.

About the Phase 1 PRO-1A-101 Study

PRO-1A-101 was a first-in-human, randomized, double-blind, placebo-controlled four-part Phase 1 study that evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), food effect (FE), and drug-drug interaction (DDI) potential of PROT-001 in healthy adult participants. Part 1 was a single ascending dose (SAD) study. Part 2 was a multiple ascending dose (MAD) study. Part 3 was a non-randomized FE cross-over study. Part 4 was a non-randomized, open-label study that evaluated potential precipitant DDIs of PROT-001. Additional information on this study can be found on ClinicalTrials.gov under the identifier NCT06981299.

About AL Amyloidosis

Immunoglobulin light chain (AL) amyloidosis is a rare, life-threatening disease affecting over 5,100 newly diagnosed patients annually and 28,000 US adults in which abnormal plasma cells produce light chain proteins that can misfold and aggregate. The direct toxicity of disease-related light chains and their accumulation as amyloid deposits in tissues both result in injury to organs, including the heart and kidneys. Cardiac injury is particularly serious, as toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart. Current treatments focus on reducing light chain production with plasma cell-directed therapies and managing organ complications, leaving patients with a substantial need for complementary approaches that directly address light chain toxicity and improve organ outcomes.

SOURCE Protego Biopharma

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302924480
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): The TARGET contains an unsupported factual claim: 'weeks after the FDA cleared the company.' The SOURCE only states the FDA clearance was 'recently announced' and provides no specific timing. Remove or revise this phrase to match the SOURCE.
Source Name
Unknown Company
Original Summary

<p>- Phase 1 results in healthy volunteers characterize the clinical profile of PROT-001, an investigational first-in-class lambda light chain kinetic stabilizer - Preclinical presentations to evaluate PROT-001's potential to reduce light chain-induced cardiac toxicity in AL amyloidosis and...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1763404/Protego-Logo-Logo.jpg?id=OA3046110&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Protego to Present Five PROT-001 Datasets at ISA 2026 After FDA Nod", "body_html": "<p><strong>SAN DIEGO -- [CURRENT_DATE] --</strong> Protego Biopharma will present five datasets on its lead candidate PROT-001 at the XX International Symposium on Amyloidosis (ISA 2026) on November 15-18, 2026, weeks after the FDA cleared the company to start its Phase 2/3 SHIELD-AL study in AL amyloidosis.</p><p>The program includes four discussed E-poster presentations and one traditional poster. SHIELD-AL will test PROT-001 added to standard of care in AL amyloidosis patients.</p><h5>Phase 1 data in healthy volunteers headline the program on November 16</h5><p>Protego will present results from the Phase 1 PRO-1A-101 study (abstract 32458) on Monday, November 16, from 10:35 to 11:00 AM in E-poster Session 1. PRO-1A-101 was a first-in-human, randomized, double-blind, placebo-controlled, four-part study in healthy adults. It evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, food effect and drug-drug interaction potential. The study is registered as NCT06981299.</p><p>PROT-001 is described as a first-in-class lambda light chain kinetic stabilizer. It is an investigational small-molecule pharmacological chaperone.</p><h5>Preclinical work targets cardiac toxicity and bortezomib compatibility</h5><p>Three presentations are scheduled for Tuesday, November 17, from 11:00 AM to 12:00 PM in E-poster Session 10:</p><ul><li>Abstract 32147 reports that PROT-001 is compatible with bortezomib-based regimens while preserving plasma cell cytotoxicity.</li><li>Abstract 32266 reports that PROT-001 suppresses amyloidogenic light chain-induced BNP signaling and cardiotoxicity in human cardiomyocytes.</li><li>Abstract 32645 describes AmyLiteDx, a mass spectrometry-based platform for analyzing amyloidogenic immunoglobulin light chains in AL amyloidosis.</li></ul><p>A fifth presentation (abstract 32646), a retrospective study of cardiac biomarkers in patients with AL cardiac amyloidosis, will appear in the General Poster Session on November 17.</p><h5>Protego pitches PROT-001 as a complement to plasma cell-directed therapy</h5><p>CEO Brent J. Warner described PROT-001 as \"a distinct approach that could complement therapies directed at the plasma cells that produce them.\" He said the company believes the approach could help patients achieve faster and deeper organ responses beyond standard of care alone. He added that deeper cardiac responses are associated with improved survival.</p><p>Current AL amyloidosis treatments reduce light chain production with plasma cell-directed therapies and manage organ complications. The disease affects more than 5,100 newly diagnosed patients annually and 28,000 US adults. Toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart.</p>", "meta_description": "Protego Biopharma will present five datasets on PROT-001 at ISA 2026 on Nov. 15-18, including Phase 1 results, after FDA cleared its Phase 2/3 SHIELD-AL study.", "seo_keywords": "Protego Biopharma, PROT-001, AL amyloidosis, ISA 2026, SHIELD-AL, light chain stabilizer, AmyLiteDx, bortezomib, Phase 2/3, protein misfolding", "companies": ["Protego Biopharma"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["event_participation", "clinical_trial_update"], "products": ["PROT-001"], "themes": ["clinical_development", "rare_disease", "diagnostics"], "events": ["XX International Symposium on Amyloidosis (ISA 2026)"], "cta_text": "Learn more about Protego Biopharma and its PROT-001 program", "learn_more": "https://www.protegobio.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
706714212055e323247d490817ba4885
Company Website
Company Website